Denosumab: Benefits of RANK ligand inhibition in cancer patients

Allan Lipton, Ira Jacobs

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Purpose of review RANK ligand (RANKL) plays a central role in the cancer-induced bone destruction that results from bone metastasis. The RANKL inhibitor denosumab was recently approved for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. This review summarizes recent findings of the effects of RANKL inhibition and denosumab in the cancer setting. Recent findings Preclinical data show that RANKL inhibition in combination with antitumor therapies has additive effects on preventing skeletal tumor progression. Preclinical breast cancer models also suggest RANKL may be involved in primary tumorigenesis and establishment of metastases in bone and other tissues. Pivotal clinical trial data with denosumab in advanced cancer patients across tumor types showed it was superior (breast and prostate) or noninferior trending toward superior (solid tumors/multiple myeloma) to zoledronic acid, in reducing the risk of developing an SRE and demonstrated a favorable safety profile. Denosumab has also demonstrated efficacy in the treatment of giant cell tumor of bone. Summary Denosumab offers an important new treatment option for patients with solid tumors and bone metastases. The efficacy of RANKL inhibition with denosumab in other disease states in the cancer setting continues to be evaluated.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalCurrent Opinion in Supportive and Palliative Care
Volume5
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

RANK Ligand
Neoplasms
Neoplasm Metastasis
Bone and Bones
zoledronic acid
Giant Cell Tumor of Bone
Bone Neoplasms
Denosumab
Multiple Myeloma
Prostate
Carcinogenesis
Breast
Clinical Trials
Breast Neoplasms
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Oncology(nursing)
  • Critical Care and Intensive Care Medicine

Cite this

@article{5c24c6b56bca4fa7b9f6d5736f6dd671,
title = "Denosumab: Benefits of RANK ligand inhibition in cancer patients",
abstract = "Purpose of review RANK ligand (RANKL) plays a central role in the cancer-induced bone destruction that results from bone metastasis. The RANKL inhibitor denosumab was recently approved for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. This review summarizes recent findings of the effects of RANKL inhibition and denosumab in the cancer setting. Recent findings Preclinical data show that RANKL inhibition in combination with antitumor therapies has additive effects on preventing skeletal tumor progression. Preclinical breast cancer models also suggest RANKL may be involved in primary tumorigenesis and establishment of metastases in bone and other tissues. Pivotal clinical trial data with denosumab in advanced cancer patients across tumor types showed it was superior (breast and prostate) or noninferior trending toward superior (solid tumors/multiple myeloma) to zoledronic acid, in reducing the risk of developing an SRE and demonstrated a favorable safety profile. Denosumab has also demonstrated efficacy in the treatment of giant cell tumor of bone. Summary Denosumab offers an important new treatment option for patients with solid tumors and bone metastases. The efficacy of RANKL inhibition with denosumab in other disease states in the cancer setting continues to be evaluated.",
author = "Allan Lipton and Ira Jacobs",
year = "2011",
month = "9",
day = "1",
doi = "10.1097/SPC.0b013e328349731c",
language = "English (US)",
volume = "5",
pages = "258--264",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Denosumab : Benefits of RANK ligand inhibition in cancer patients. / Lipton, Allan; Jacobs, Ira.

In: Current Opinion in Supportive and Palliative Care, Vol. 5, No. 3, 01.09.2011, p. 258-264.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Denosumab

T2 - Benefits of RANK ligand inhibition in cancer patients

AU - Lipton, Allan

AU - Jacobs, Ira

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Purpose of review RANK ligand (RANKL) plays a central role in the cancer-induced bone destruction that results from bone metastasis. The RANKL inhibitor denosumab was recently approved for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. This review summarizes recent findings of the effects of RANKL inhibition and denosumab in the cancer setting. Recent findings Preclinical data show that RANKL inhibition in combination with antitumor therapies has additive effects on preventing skeletal tumor progression. Preclinical breast cancer models also suggest RANKL may be involved in primary tumorigenesis and establishment of metastases in bone and other tissues. Pivotal clinical trial data with denosumab in advanced cancer patients across tumor types showed it was superior (breast and prostate) or noninferior trending toward superior (solid tumors/multiple myeloma) to zoledronic acid, in reducing the risk of developing an SRE and demonstrated a favorable safety profile. Denosumab has also demonstrated efficacy in the treatment of giant cell tumor of bone. Summary Denosumab offers an important new treatment option for patients with solid tumors and bone metastases. The efficacy of RANKL inhibition with denosumab in other disease states in the cancer setting continues to be evaluated.

AB - Purpose of review RANK ligand (RANKL) plays a central role in the cancer-induced bone destruction that results from bone metastasis. The RANKL inhibitor denosumab was recently approved for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. This review summarizes recent findings of the effects of RANKL inhibition and denosumab in the cancer setting. Recent findings Preclinical data show that RANKL inhibition in combination with antitumor therapies has additive effects on preventing skeletal tumor progression. Preclinical breast cancer models also suggest RANKL may be involved in primary tumorigenesis and establishment of metastases in bone and other tissues. Pivotal clinical trial data with denosumab in advanced cancer patients across tumor types showed it was superior (breast and prostate) or noninferior trending toward superior (solid tumors/multiple myeloma) to zoledronic acid, in reducing the risk of developing an SRE and demonstrated a favorable safety profile. Denosumab has also demonstrated efficacy in the treatment of giant cell tumor of bone. Summary Denosumab offers an important new treatment option for patients with solid tumors and bone metastases. The efficacy of RANKL inhibition with denosumab in other disease states in the cancer setting continues to be evaluated.

UR - http://www.scopus.com/inward/record.url?scp=80052753612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052753612&partnerID=8YFLogxK

U2 - 10.1097/SPC.0b013e328349731c

DO - 10.1097/SPC.0b013e328349731c

M3 - Review article

C2 - 21826000

AN - SCOPUS:80052753612

VL - 5

SP - 258

EP - 264

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 3

ER -